431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumorsSarah P. Blagden, Johann S. de Bono, Hanine Medani et al.|European Journal of Cancer Supplements|2008Cited by 4
Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancerSarah P. Blagden, Johann S. de Bono, David Olmos et al.|European Journal of Cancer Supplements|2008Cited by 2